## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re A	Application of:	)	
<b>.</b>		)	Conf No.: 1789
John	F. R. Robertson et al.	)	
		)	Art Unit: <b>1643</b>
Serial No. <b>10/534,773</b>		)	
		)	Examiner: Lynn Anne Bristol
Filed:	May 13, 2005	)	
		)	
For:	<b>Tumour Marker Proteins and Uses</b>	)	
	Thereof	)	

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

The citation of information on the attached Form PTO/SB/08 is made pursuant to 37 C.F.R. §§ 1.56, 1.97, and 1.98. A copy of each cited item is enclosed except for U.S. patents and U.S. patent application publications.

INFORMATION DISCLOSURE STATEMENT

The citation of this information does not constitute an admission of priority or that any cited item is available as a reference, or a waiver of any right the applicant may have under applicable statutes, Rules of Practice in patent cases, or otherwise.

Applicants state that each item of information contained in the information disclosure statement was first cited in any communication in a counterpart U.S. application not more than three months prior to the filing of the information disclosure statement. Applicant believes that no fee is due for consideration of this paper. If a fee is due, the

I certify that this correspondence is being filed with the U.S. Patent and	<b>Frademark</b>
Office via EFS Web on June <u>1</u> , 2009.	

/Janie Wilkins 65/1/		_
Jar	nie Wilkins	
US2000 11364668.1		

## Commissioner is authorized to charge said fee to Deposit Account No. 11-0855.

Respectfully submitted,

/Kimberly L. Thomason/

Kimberly L. Thomason Reg. No. 60,942

KILPATRICK STOCKTON LLP 1100 Peachtree Street Suite 2800 Atlanta, Georgia 30309-4530 (404) 815-6500 Our Docket: 49409-0041 (315804)

US2000 11364668.1